Current status of research on intrauterine devices.
D015119:Aminocaproic Acid / Q000009:adverse effects; D000818:Animals; D001792:Blood Platelets / Q000502:physiology; D002738:Chloroquine / Q000009:adverse effects; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors; D004717:Endometrium / Q000166:cytology; D005260:Female; D005341:Fibrinolysin / Q000032:analysis; D006493:Heparin / Q000032:analysis; D006634:Histamine H1 Antagonists / Q000009:adverse effects; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects*; D007435:Intrauterine Devices, Copper / Q000009:adverse effects; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D008407:Mast Cells / Q000502:physiology; D008598:Menstruation / Q000187:drug effects; D009640:Norethindrone / Q000494:pharmacology; D009644:Norgestrel / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D014944:World Health Organization
D016861:Cyclooxygenase Inhibitors; D006634:Histamine H1 Antagonists; D009644:Norgestrel; D011374:Progesterone; D002738:Chloroquine; D006493:Heparin; D005341:Fibrinolysin; D009640:Norethindrone; D015119:Aminocaproic Acid